Remote controlling biological systems by sonopharmacology and sonogenetics

This project aims to develop biocompatible ultrasound technology to control drug, protein, and gene activity, enhancing therapies for cancer, diabetes, and tissue engineering while minimizing side effects.

Subsidie
€ 2.500.000
2024

Projectdetails

Introduction

To date, light has been employed as a widespread trigger to achieve control over the activity of drugs and protein function, establishing the fields of photopharmacology and optogenetics, respectively. Both techniques led to promising new therapies, the elucidation of brain function, or understanding of neural disorders.

Limitations of Current Techniques

However, serious limitations resulting from the low penetration depth of light into tissues are severely hampering progress in these fields. In contrast to photons, ultrasound deeply penetrates tissue and can be applied with sub-millimeter resolution. Consequently, it has been widely established in the clinic over many decades for therapy and diagnostics.

Project Overview

In this ERC Advanced Grant, I will develop a radically new approach to control the activity of drugs, proteins, and genes by biocompatible ultrasound. Polynucleic acid carriers, which can bind a wide variety of bioactive payloads, will be designed to be sensitive to different ultrasound sources. These sources can be applied in clinical settings and do not harm cells or tissues.

Mechanism of Action

Upon ultrasound irradiation, these carriers liberate their bioactive payloads by mechanochemical principles to switch on drugs and control cellular functions.

Research Objectives

To achieve this aim, I will:

  1. Investigate the effect of ultrasound (US) on nucleic acid architectures.
  2. Study the loading of polynucleic acids with different payloads and their release by US.
  3. Develop a technology platform to activate small molecule drugs, proteins, and oligonucleotides.
  4. Showcase the huge potential of these technologies for cancer immunotherapy, diabetes research, and tissue engineering.

Expected Outcomes

This project will boost sonopharmacology and sonogenetics. Its outcomes will enable spatiotemporal control of drug action to minimize side effects in pharmacotherapy, such as cancer. The remote-controlled orchestration of protein and gene function by US will strongly advance medicine and the life sciences by answering fundamental questions in these fields.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 2.500.000
Totale projectbegroting€ 2.500.000

Tijdlijn

Startdatum1-9-2024
Einddatum31-8-2029
Subsidiejaar2024

Partners & Locaties

Projectpartners

  • DWI LEIBNIZ-INSTITUT FUR INTERAKTIVE MATERIALIEN EVpenvoerder

Land(en)

Germany

Vergelijkbare projecten binnen European Research Council

ERC Synergy ...

A sonogenetic brain-machine interface for neurosciences and visual restoration

Developing a novel sonogenetic brain-machine interface for remote, precise control of neuronal networks in large primate brains to advance treatments for neurological disorders.

€ 7.817.939
ERC Starting...

Single-Molecule Acousto-Photonic Nanofluidics

SIMPHONICS aims to develop a high-throughput, non-invasive platform for protein fingerprinting by integrating nanopore technology with acoustic manipulation and fluorescence detection.

€ 1.499.395
ERC Starting...

Deciphering the radiobiology of targeted radionuclide therapy: from subcellular to intra-tumoural analyses

This project aims to enhance targeted radionuclide therapies for metastatic cancer by elucidating radiobiological mechanisms and developing advanced imaging techniques to improve treatment strategies.

€ 1.750.000
ERC Starting...

measuriNg nEURal dynamics with label-free OpticaL multI-DomAin Recordings

This project aims to innovate label-free optical methods for monitoring neural dynamics in the brain, enhancing understanding and treatment of brain diseases without exogenous reporters.

€ 1.634.825
ERC Consolid...

Decoding subcellular spatial biology with high precision using RNA photocatalysts

This project aims to develop a low-cost, high-precision technology for deciphering RNA interactions, enhancing understanding of RNA networks and uncovering new therapeutic targets for diseases.

€ 1.999.525

Vergelijkbare projecten uit andere regelingen

EIC Pathfinder

Development of innovative proton and neutron therapies with high cancer specificity by 'hijacking' the intracellular chemistry of haem biosynthesis.

NuCapCure aims to develop novel cancer treatments for glioblastoma by utilizing custom-made drugs through biosynthesis to enhance proton and neutron therapies for better targeting and efficacy.

€ 5.972.875
EIC Pathfinder

LUMINESCENT IMPLANTS AS PORTS FOR LIGHT-BASED THERAPIES

The project aims to develop PhotoTheraPorts for localized light delivery to enhance anti-inflammatory and neuroinhibitory drug efficacy, improving treatment precision for neuropathic pain and epilepsy.

€ 2.999.840
EIC Pathfinder

A revolutionary cell programming platform based on the targeted nano-delivery of a transposon gene editing system

The NANO-ENGINE project aims to develop an affordable, scalable, and safe DNA-based in vivo cell programming technology using Targeted Nanoparticles to enhance accessibility of cell therapies for various diseases.

€ 2.988.377
EIC Pathfinder

AEGEUS - A Novel EEG Ultrasound Device for Functional Brain Imaging and Neurostimulation

Develop a novel wearable device combining ultrasound imaging and EEG for enhanced diagnosis and treatment of neurological disorders, aiming for improved patient outcomes and research advancements.

€ 2.998.988